Bausch Health Companies stock
BHCNYSEBausch Health Companies Inc., HealthcareISIN CA0717341071
61Score 61 out of 100, Neutral
Price and trend
86 / 100
Price history
+23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 45% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 6.3% below its 52-week high. Largest decline in 20 years: 98% (August 2015 to April 2025).
Chart figures for advanced users
- SMA 50$6.51
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.77
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.43
- The lowest closing price of the last twelve months.
- Resistance$8.91
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bausch Health Companies Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (Canada) and, with a market value of $3.13B, is number 46 of 78 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $11.03B (up 7.4%) and adjusted earnings per share of $4.87 (up 30.6%).
- MEQIRI Score 61 out of 100 (Neutral): rank 257 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $18.12, with the price 54% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Margin may fall backOperating margin 21.3%, average of the prior years 8.4%, which ranged from 5.3% to 16.1%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.Profitability 43
- Interest barely coveredOperating profit covers interest only 1.2 times.Stability 26
- Loss-makingLoss of $841M over the last 12 months.Fundamentals 53
Its standout strengths are valuation and momentum, while profitability and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $12.08 and expensive above $36.24 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 12.3%. At 13.3% the fair value would be $16.55, at 11.3% it would be $20.09.
Possible value trap: looks cheap, but high risk.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.8% on the twelve months before. Revenue has grown strongly since 2006, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating 21%, net 2%. Last 12 months: net −8%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 28 Oct 2026EPS reported $1.77 (expected $1.25)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 8.0% since 15 Oct 2026.
- Earnings per share
- $4.87+8.0%
- Revenue
- $11.03B+1.9%
- Earnings per share
- $4.35+1.3%
- Revenue
- $10.94B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +41.2%Bausch Health raised its full year 2026 guidance for the second time, now expecting revenue of 5.525 to 5.625 billion dollars, Adjusted EBITDA of 3.225 to 3.275 billion dollars (up 13% year over year) and operating cash flow of 1.6 to 1.675 billion dollars (up 29%).
“Adjusted EBITDA is now expected to be between $3.225 billion and $3.275 billion the midpoint of that range represents a 13% increase versus 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $391,690 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bausch Health Companies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Ipca LaboratoriesIPCALAB.NS $5.25B70
- Shenzhen Salubris Pharmaceuticals002294.SZ $5.03B53
- Laboratorios Farmaceuticos RoviROVI.MC $4.02B82
- Siegfried HoldingSFZN.SW $3.77B55
- Regencell Bioscience HoldingsRGC $2.68B31
- HUTCHMED (China)HCM $2.63B45
- AlmirallALM.MC $2.61B45
- PerrigoPRGO $2.3B48
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.